Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379806 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3EPHX2CHRM2 | |
| SCHEMBL5404302 | 0.85 | HSD17B10 (0.37) | CHRM2CHRM1CHRM3HSD17B10USP2 | |
| SCHEMBL8288621 | 0.85 | HSD17B10 (0.37) | CHRM2CHRM1CHRM3HSD17B10USP2 | |
| SCHEMBL26695036 | 0.84 | PTPN1 (0.35) | PTPN1NR1H2NR1H3EPHX2CHRM2 | |
| SCHEMBL883019 | 0.84 | PTPN1 (0.35) | PTPN1NR1H2NR1H3EPHX2CHRM2 | |
| SCHEMBL8288622 | 0.84 | SPHK1 (0.35) | NR1H2HDAC8ALDH1A1SMN1; SMN2 | |
| SCHEMBL8290019 | 0.82 | HDAC8 (0.34) | HSD17B10HDAC8ALDH1A1SMN1; SMN2 | |
| SCHEMBL883350 | 0.77 | PTPN1 (0.34) | PTPN1NR1H2NR1H3EPHX2CHRM2 | |
| SCHEMBL16914271 | 0.75 | NR1H2 (0.35) | PTPN1NR1H2NR1H3EPHX2HSD17B10 | |
| SCHEMBL16749436 | 0.74 | NR1H2 (0.35) | PTPN1NR1H2NR1H3EPHX2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737818-A2 | METHODS FOR THE PREPARATION OF STEREOISOMERICALLY ENRICHED AMINES | Pfizer, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050192441-A1 | by enzymatically hydrolyzing one stereoisomer; biocatalyst; alkaline protease, an esterase, a lipase, or a hydrolase; useful in the preparation of protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005054186-A2 | METHODS FOR THE PREPARATION OF STEREOISOMERICALLY ENRICHED AMINES | PFIZER INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054187-A1 | METHODS OF PREPARING COMPOUNDS USEFUL AS PROTEASE INHIBITORS | PFIZER INC. (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192441-A1 | by enzymatically hydrolyzing one stereoisomer; biocatalyst; alkaline protease, an esterase, a lipase, or a hydrolase; useful in the preparation of protease inhibitors | CTRL, CTRC, LIPA | PTPN1 2206/4885NR1H2 1585/4885NR1H3 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.